|Brand name(s), other common name(s)||CalquenceTM|
|Drug type||BTK inhibitor|
|How the drug is given||By mouth|
Indications and Usage
Acalabrutinib is FDA approved for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.
Side effects needing medical attention
Headache, diarrhea, bruising, fatigue and muscle pain (myalgia), and reduced levels of red blood cells (anemia), platelets (thrombocytopenia) and neutrophils (neutropenia) in the blood.
Serious side effects include bleeding (hemorrhage), infections and irregular heartbeat (atrial fibrillation). Additional cancers, known as second primary malignancies, have occurred in some patients taking Calquence.